A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 800 participants.
Also called NCT07662044
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 800 participants
- Sponsor
- Registry
-
NCT07662044 -
2025-523936-37-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, China, Denmark, Greece, Hungary, Japan, Slovakia, South Africa, South Korea, Spain, Taiwan, Türkiye
- Registry status
- Recruiting
Technical summary
Registry record NCT07662044. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-07-14 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
- Acronym
- Eluminate-1
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Elecoglipron
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Elecoglipron-matched placebo
- Intervention (Drug)
- Dapagliflozin-matched placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07662044- Content hash
a3441eef5c6b66e25e292186434c627d8aba22675ad4e1511a0700c6fc5d18c4